Upgrades
According to Goldman Sachs, the prior rating for FREYR Battery (NYSE:FREY) was changed from Neutral to Buy. In the second quarter, FREYR Battery showed an EPS of $0.24, compared to $0.04 from the year-ago quarter. At the moment, the stock has a 52-week-high of $13.54 and a 52-week-low of $6.42. FREYR Battery closed at $10.57 at the end of the last trading period.
Berenberg upgraded the previous rating for Kosmos Energy Ltd (NYSE:KOS) from Hold to Buy. In the second quarter, Kosmos Energy showed an EPS of $0.28, compared to $0.03 from the year-ago quarter. The current stock performance of Kosmos Energy shows a 52-week-high of $8.48 and a 52-week-low of $3.45. Moreover, at the end of the last trading period, the closing price was at $6.77.
B of A Securities upgraded the previous rating for Dream Finders Homes Inc (NASDAQ:DFH) from Underperform to Neutral. For the second quarter, Dream Finders Homes had an EPS of $0.60, compared to year-ago quarter EPS of $0.31. The stock has a 52-week-high of $23.09 and a 52-week-low of $9.60. At the end of the last trading period, Dream Finders Homes closed at $11.43.
According to Morgan Stanley, the prior rating for Stride Inc (NYSE:LRN) was changed from Equal-Weight to Overweight. For the fourth quarter, Stride had an EPS of $0.66, compared to year-ago quarter EPS of $0.25. The current stock performance of Stride shows a 52-week-high of $44.93 and a 52-week-low of $25.65. Moreover, at the end of the last trading period, the closing price was at $35.52.
Stifel upgraded the previous rating for Verve Therapeutics Inc (NASDAQ:VERV) from Hold to Buy. For the second quarter, Verve Therapeutics had an EPS of $0.84, compared to year-ago quarter EPS of $6.66. The stock has a 52-week-high of $41.30 and a 52-week-low of $10.70. At the end of the last trading period, Verve Therapeutics closed at $40.12.
See all analyst ratings upgrades.
Downgrades
For GDS Holdings Ltd (NASDAQ:GDS), Daiwa Capital downgraded the previous rating of Outperform to Hold. For the second quarter, GDS Holdings had an EPS of $0.32, compared to year-ago quarter EPS of $0.28. The current stock performance of GDS Holdings shows a 52-week-high of $48.42 and a 52-week-low of $19.83. Moreover, at the end of the last trading period, the closing price was at $26.91.
According to B of A Securities, the prior rating for Toll Brothers Inc (NYSE:TOL) was changed from Buy to Neutral. In the third quarter, Toll Brothers showed an EPS of $2.35, compared to $1.87 from the year-ago quarter. The current stock performance of Toll Brothers shows a 52-week-high of $72.75 and a 52-week-low of $40.20. Moreover, at the end of the last trading period, the closing price was at $46.22.
For GDS Holdings Ltd (NASDAQ:GDS), Deutsche Bank downgraded the previous rating of Buy to Hold. In the second quarter, GDS Holdings showed an EPS of $0.32, compared to $0.28 from the year-ago quarter. At the moment, the stock has a 52-week-high of $48.42 and a 52-week-low of $19.83. GDS Holdings closed at $26.91 at the end of the last trading period.
According to B of A Securities, the prior rating for KB Home (NYSE:KBH) was changed from Buy to Neutral. For the second quarter, KB Home had an EPS of $2.32, compared to year-ago quarter EPS of $1.50. The current stock performance of KB Home shows a 52-week-high of $50.20 and a 52-week-low of $24.78. Moreover, at the end of the last trading period, the closing price was at $30.26.
B of A Securities downgraded the previous rating for Lennar Corp (NYSE:LEN) from Neutral to Underperform. Lennar earned $4.69 in the second quarter, compared to $2.95 in the year-ago quarter. At the moment, the stock has a 52-week-high of $116.36 and a 52-week-low of $62.54. Lennar closed at $83.80 at the end of the last trading period.
For GDS Holdings Ltd (NASDAQ:GDS), JP Morgan downgraded the previous rating of Overweight to Neutral. GDS Holdings earned $0.32 in the second quarter, compared to $0.28 in the year-ago quarter. The current stock performance of GDS Holdings shows a 52-week-high of $48.42 and a 52-week-low of $19.83. Moreover, at the end of the last trading period, the closing price was at $26.91.
According to Raymond James, the prior rating for La-Z-Boy Inc (NYSE:LZB) was changed from Outperform to Market Perform. La-Z-Boy earned $0.91 in the first quarter, compared to $0.55 in the year-ago quarter. The current stock performance of La-Z-Boy shows a 52-week-high of $38.16 and a 52-week-low of $22.21. Moreover, at the end of the last trading period, the closing price was at $29.18.
For Akerna Corp (NASDAQ:KERN), HC Wainwright & Co. downgraded the previous rating of Buy to Neutral. For the second quarter, Akerna had an EPS of $0.15, compared to year-ago quarter EPS of $0.27. The current stock performance of Akerna shows a 52-week-high of $1.92 and a 52-week-low of $0.12. Moreover, at the end of the last trading period, the closing price was at $0.13.
According to Goldman Sachs, the prior rating for Krystal Biotech Inc (NASDAQ:KRYS) was changed from Buy to Neutral. Krystal Biotech earned $1.10 in the second quarter, compared to $0.74 in the year-ago quarter. The stock has a 52-week-high of $85.11 and a 52-week-low of $47.67. At the end of the last trading period, Krystal Biotech closed at $76.81.
Goldman Sachs downgraded the previous rating for Edgewise Therapeutics Inc (NASDAQ:EWTX) from Neutral to Sell. In the second quarter, Edgewise Therapeutics showed an EPS of $0.32, compared to $0.21 from the year-ago quarter. The current stock performance of Edgewise Therapeutics shows a 52-week-high of $20.71 and a 52-week-low of $5.41. Moreover, at the end of the last trading period, the closing price was at $11.02.
For Magenta Therapeutics Inc (NASDAQ:MGTA), Goldman Sachs downgraded the previous rating of Buy to Neutral. In the second quarter, Magenta Therapeutics showed an EPS of $0.29, compared to $0.32 from the year-ago quarter. At the moment, the stock has a 52-week-high of $5.49 and a 52-week-low of $0.92. Magenta Therapeutics closed at $1.94 at the end of the last trading period.
See all analyst ratings downgrades.
Initiations
With a Buy rating, JonesTrading initiated coverage on Satsuma Pharmaceuticals Inc (NASDAQ:STSA). The price target seems to have been set at $14.00 for Satsuma Pharmaceuticals. Satsuma Pharmaceuticals earned $0.52 in the second quarter, compared to $0.38 in the year-ago quarter. At the moment, the stock has a 52-week-high of $6.52 and a 52-week-low of $2.51. Satsuma Pharmaceuticals closed at $6.03 at the end of the last trading period.
With a Buy rating, JonesTrading initiated coverage on Impel Pharmaceuticals Inc (NASDAQ:IMPL). The price target seems to have been set at $26.00 for Impel Pharmaceuticals. In the second quarter, Impel Pharmaceuticals showed an EPS of $1.09, compared to $0.79 from the year-ago quarter. The current stock performance of Impel Pharmaceuticals shows a 52-week-high of $10.75 and a 52-week-low of $5.72. Moreover, at the end of the last trading period, the closing price was at $7.57.
With a Buy rating, JonesTrading initiated coverage on Concert Pharmaceuticals Inc (NASDAQ:CNCE). The price target seems to have been set at $17.00 for Concert Pharma. Concert Pharma earned $0.59 in the second quarter, compared to $0.16 in the year-ago quarter. The stock has a 52-week-high of $7.37 and a 52-week-low of $2.57. At the end of the last trading period, Concert Pharma closed at $7.19.
With an Outperform rating, Credit Suisse initiated coverage on Maravai LifeSciences Holdings Inc (NASDAQ:MRVI). The price target seems to have been set at $34.00 for Maravai LifeSciences. In the second quarter, Maravai LifeSciences showed an EPS of $0.54, compared to $0.44 from the year-ago quarter. At the moment, the stock has a 52-week-high of $41.87 and a 52-week-low of $23.05. Maravai LifeSciences closed at $23.27 at the end of the last trading period.
Credit Suisse initiated coverage on Adaptive Biotechnologies Corp (NASDAQ:ADPT) with an Underperform rating. The price target for Adaptive Biotechnologies is set to $8.00. For the second quarter, Adaptive Biotechnologies had an EPS of $0.37, compared to year-ago quarter EPS of $0.35. At the moment, the stock has a 52-week-high of $28.92 and a 52-week-low of $5.96. Adaptive Biotechnologies closed at $11.18 at the end of the last trading period.
With a Buy rating, EF Hutton initiated coverage on FiscalNote Holdings Inc (NYSE:NOTE). The price target seems to have been set at $12.00 for FiscalNote Holdings. The current stock performance of FiscalNote Holdings shows a 52-week-high of $12.30 and a 52-week-low of $5.55. Moreover, at the end of the last trading period, the closing price was at $9.93.
Redburn Partners initiated coverage on Getty Images Holdings Inc (NYSE:GETY) with a Neutral rating. The current stock performance of Getty Images Holdings shows a 52-week-high of $37.88 and a 52-week-low of $8.08. Moreover, at the end of the last trading period, the closing price was at $29.05.
CJS Securities initiated coverage on Central Garden & Pet Co (NASDAQ:CENT) with a Market Outperform rating. The price target for Central Garden & Pet is set to $50.00. In the third quarter, Central Garden & Pet showed an EPS of $1.39, compared to $1.37 from the year-ago quarter. The stock has a 52-week-high of $53.40 and a 52-week-low of $40.03. At the end of the last trading period, Central Garden & Pet closed at $42.56.
For Shutterstock Inc (NYSE:SSTK), Redburn Partners initiated coverage, by setting the current rating at Buy. For the second quarter, Shutterstock had an EPS of $0.83, compared to year-ago quarter EPS of $1.02. The current stock performance of Shutterstock shows a 52-week-high of $111.66 and a 52-week-low of $50.04. Moreover, at the end of the last trading period, the closing price was at $57.36.
With an Outperform rating, Oppenheimer initiated coverage on Pennant Group Inc (NASDAQ:PNTG). The price target seems to have been set at $22.00 for Pennant Gr. Pennant Gr earned $0.14 in the second quarter, compared to $0.17 in the year-ago quarter. At the moment, the stock has a 52-week-high of $24.23 and a 52-week-low of $10.07. Pennant Gr closed at $16.48 at the end of the last trading period.
With a Equal-Weight rating, Wells Fargo initiated coverage on NuScale Power Corp (NYSE:SMR). The price target seems to have been set at $17.00 for NuScale Power. In the second quarter, NuScale Power showed an EPS of $0.08, compared to $0.10 from the year-ago quarter. The stock has a 52-week-high of $15.85 and a 52-week-low of $8.87. At the end of the last trading period, NuScale Power closed at $15.32.
EF Hutton initiated coverage on One Liberty Properties Inc (NYSE:OLP) with a Buy rating. The price target for One Liberty Props is set to $30.00. For the second quarter, One Liberty Props had an EPS of $0.49, compared to year-ago quarter EPS of $0.48. At the moment, the stock has a 52-week-high of $36.60 and a 52-week-low of $24.33. One Liberty Props closed at $24.89 at the end of the last trading period.
SVB Leerink initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) with an Outperform rating. The price target for MoonLake is set to $17.00. The stock has a 52-week-high of $15.00 and a 52-week-low of $4.25. At the end of the last trading period, MoonLake closed at $9.01.
With a Neutral rating, Credit Suisse initiated coverage on Enhabit Inc (NYSE:EHAB). The price target seems to have been set at $19.00 for Enhabit. At the moment, the stock has a 52-week-high of $23.51 and a 52-week-low of $11.65. Enhabit closed at $15.85 at the end of the last trading period.
With a Buy rating, Ladenburg Thalmann initiated coverage on Kiora Pharmaceuticals Inc (NASDAQ:KPRX). The price target seems to have been set at $6.50 for Kiora Pharmaceuticals. In the second quarter, Kiora Pharmaceuticals showed an EPS of $0.18, compared to $0.39 from the year-ago quarter. The current stock performance of Kiora Pharmaceuticals shows a 52-week-high of $1.42 and a 52-week-low of $0.12. Moreover, at the end of the last trading period, the closing price was at $0.13.
With a Equal-Weight rating, Morgan Stanley initiated coverage on Kinetik Holdings Inc (NASDAQ:KNTK). The price target seems to have been set at $46.00 for Kinetik Holdings. In the second quarter, Kinetik Holdings showed an EPS of $0.06, compared to $0.72 from the year-ago quarter. The stock has a 52-week-high of $87.70 and a 52-week-low of $31.34. At the end of the last trading period, Kinetik Holdings closed at $38.54.
Piper Sandler initiated coverage on NICE Ltd (NASDAQ:NICE) with a Neutral rating. The price target for NICE is set to $236.00. NICE earned $1.86 in the second quarter, compared to $1.57 in the year-ago quarter. The current stock performance of NICE shows a 52-week-high of $306.12 and a 52-week-low of $179.13. Moreover, at the end of the last trading period, the closing price was at $219.71.
Piper Sandler initiated coverage on Avidbank Holdings Inc (OTC:AVBH) with an Overweight rating. The price target for Avidbank Holdings is set to $24.00.
B. Riley Securities initiated coverage on Actinium Pharmaceuticals Inc (AMEX:ATNM) with a Buy rating. The price target for Actinium Pharmaceuticals is set to $16.00. For the second quarter, Actinium Pharmaceuticals had an EPS of $0.33, compared to year-ago quarter EPS of $0.25. The stock has a 52-week-high of $7.49 and a 52-week-low of $4.41. At the end of the last trading period, Actinium Pharmaceuticals closed at $6.18.
For NOV Inc (NYSE:NOV), Benchmark initiated coverage, by setting the current rating at Hold. In the second quarter, NOV showed an EPS of $0.18, compared to $0.07 from the year-ago quarter. The stock has a 52-week-high of $24.06 and a 52-week-low of $13.62. At the end of the last trading period, NOV closed at $18.81.
Benchmark initiated coverage on ChampionX Corp (NASDAQ:CHX) with a Buy rating. The price target for ChampionX is set to $32.00. In the second quarter, ChampionX showed an EPS of $0.28, compared to $0.11 from the year-ago quarter. The current stock performance of ChampionX shows a 52-week-high of $26.98 and a 52-week-low of $16.64. Moreover, at the end of the last trading period, the closing price was at $23.15.
Benchmark initiated coverage on TechnipFMC PLC (NYSE:FTI) with a Buy rating. The price target for TechnipFMC is set to $12.00. In the second quarter, TechnipFMC showed an EPS of $0.02, compared to $0.06 from the year-ago quarter. The stock has a 52-week-high of $9.10 and a 52-week-low of $5.47. At the end of the last trading period, TechnipFMC closed at $8.67.
With a Neutral rating, Credit Suisse initiated coverage on Avantor Inc (NYSE:AVTR). The price target seems to have been set at $32.00 for Avantor. Avantor earned $0.37 in the second quarter, compared to $0.35 in the year-ago quarter. The current stock performance of Avantor shows a 52-week-high of $41.98 and a 52-week-low of $25.53. Moreover, at the end of the last trading period, the closing price was at $26.01.
Credit Suisse initiated coverage on Exact Sciences Corp (NASDAQ:EXAS) with an Outperform rating. The price target for Exact Sciences is set to $55.00. For the second quarter, Exact Sciences had an EPS of $0.90, compared to year-ago quarter EPS of $1.03. The stock has a 52-week-high of $84.46 and a 52-week-low of $34.78. At the end of the last trading period, Exact Sciences closed at $37.39.
Credit Suisse initiated coverage on Certara Inc (NASDAQ:CERT) with an Outperform rating. The price target for Certara is set to $22.00. For the second quarter, Certara had an EPS of $0.09, compared to year-ago quarter EPS of $0.03. The stock has a 52-week-high of $29.04 and a 52-week-low of $15.83. At the end of the last trading period, Certara closed at $16.27.
With an Outperform rating, Credit Suisse initiated coverage on Fulgent Genetics Inc (NASDAQ:FLGT). The price target seems to have been set at $65.00 for Fulgent Genetics. Fulgent Genetics earned $0.78 in the second quarter, compared to $2.55 in the year-ago quarter. The current stock performance of Fulgent Genetics shows a 52-week-high of $101.98 and a 52-week-low of $46.50. Moreover, at the end of the last trading period, the closing price was at $46.96.
With a Neutral rating, Credit Suisse initiated coverage on Thermo Fisher Scientific Inc (NYSE:TMO). The price target seems to have been set at $675.00 for Thermo Fisher Scientific. Thermo Fisher Scientific earned $5.51 in the second quarter, compared to $5.60 in the year-ago quarter. The stock has a 52-week-high of $664.27 and a 52-week-low of $497.83. At the end of the last trading period, Thermo Fisher Scientific closed at $573.15.
With an Outperform rating, Credit Suisse initiated coverage on Danaher Corp (NYSE:DHR). The price target seems to have been set at $340.00 for Danaher. Danaher earned $2.76 in the second quarter, compared to $2.46 in the year-ago quarter. At the moment, the stock has a 52-week-high of $328.57 and a 52-week-low of $233.71. Danaher closed at $284.94 at the end of the last trading period.
With an Outperform rating, Credit Suisse initiated coverage on Guardant Health Inc (NASDAQ:GH). The price target seems to have been set at $80.00 for Guardant Health. For the second quarter, Guardant Health had an EPS of $1.00, compared to year-ago quarter EPS of $0.61. The current stock performance of Guardant Health shows a 52-week-high of $102.85 and a 52-week-low of $27.65. Moreover, at the end of the last trading period, the closing price was at $50.35.
Credit Suisse initiated coverage on Bio-Rad Laboratories Inc (NYSE:BIO) with an Outperform rating. The price target for Bio-Rad Laboratories is set to $715.00. Bio-Rad Laboratories earned $3.38 in the second quarter, compared to $3.54 in the year-ago quarter. The current stock performance of Bio-Rad Laboratories shows a 52-week-high of $752.17 and a 52-week-low of $462.61. Moreover, at the end of the last trading period, the closing price was at $499.09.
Credit Suisse initiated coverage on PerkinElmer Inc (NYSE:PKI) with a Neutral rating. The price target for PerkinElmer is set to $175.00. In the second quarter, PerkinElmer showed an EPS of $2.32, compared to $2.83 from the year-ago quarter. The current stock performance of PerkinElmer shows a 52-week-high of $201.05 and a 52-week-low of $130.65. Moreover, at the end of the last trading period, the closing price was at $141.39.
With an Outperform rating, Credit Suisse initiated coverage on Natera Inc (NASDAQ:NTRA). The price target seems to have been set at $70.00 for Natera. For the second quarter, Natera had an EPS of $1.50, compared to year-ago quarter EPS of $1.32. At the moment, the stock has a 52-week-high of $92.06 and a 52-week-low of $26.10. Natera closed at $52.06 at the end of the last trading period.
With a Neutral rating, Credit Suisse initiated coverage on Waters Corp (NYSE:WAT). The price target seems to have been set at $345.00 for Waters. In the second quarter, Waters showed an EPS of $2.75, compared to $2.60 from the year-ago quarter. The current stock performance of Waters shows a 52-week-high of $372.24 and a 52-week-low of $288.32. Moreover, at the end of the last trading period, the closing price was at $316.88.
With a Neutral rating, Credit Suisse initiated coverage on Icon PLC (NASDAQ:ICLR). The price target seems to have been set at $260.00 for Icon. In the second quarter, Icon showed an EPS of $2.86, compared to $2.12 from the year-ago quarter. At the moment, the stock has a 52-week-high of $312.28 and a 52-week-low of $196.34. Icon closed at $227.33 at the end of the last trading period.
Credit Suisse initiated coverage on IQVIA Holdings Inc (NYSE:IQV) with an Outperform rating. The price target for IQVIA Hldgs is set to $300.00. IQVIA Hldgs earned $2.44 in the second quarter, compared to $2.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $282.52 and a 52-week-low of $194.67. IQVIA Hldgs closed at $231.83 at the end of the last trading period.
With an Outperform rating, Credit Suisse initiated coverage on Bio-Techne Corp (NASDAQ:TECH). The price target seems to have been set at $465.00 for Bio-Techne. In the fourth quarter, Bio-Techne showed an EPS of $2.05, compared to $1.87 from the year-ago quarter. The stock has a 52-week-high of $519.05 and a 52-week-low of $318.07. At the end of the last trading period, Bio-Techne closed at $346.98.
With a Neutral rating, Credit Suisse initiated coverage on Illumina Inc (NASDAQ:ILMN). The price target seems to have been set at $230.00 for Illumina. Illumina earned $0.57 in the second quarter, compared to $1.87 in the year-ago quarter. The current stock performance of Illumina shows a 52-week-high of $428.00 and a 52-week-low of $173.45. Moreover, at the end of the last trading period, the closing price was at $210.75.
Credit Suisse initiated coverage on Invitae Corp (NYSE:NVTA) with an Underperform rating. The price target for Invitae is set to $1.00. For the second quarter, Invitae had an EPS of $0.68, compared to year-ago quarter EPS of $0.85. The current stock performance of Invitae shows a 52-week-high of $15.87 and a 52-week-low of $1.83. Moreover, at the end of the last trading period, the closing price was at $3.69.
Credit Suisse initiated coverage on Agilent Technologies Inc (NYSE:A) with an Outperform rating. The price target for Agilent Technologies is set to $165.00. Agilent Technologies earned $1.34 in the third quarter, compared to $1.10 in the year-ago quarter. The stock has a 52-week-high of $159.44 and a 52-week-low of $112.52. At the end of the last trading period, Agilent Technologies closed at $133.67.
With an Outperform rating, Credit Suisse initiated coverage on Charles River Laboratories International Inc (NYSE:CRL). The price target seems to have been set at $285.00 for Charles River. For the second quarter, Charles River had an EPS of $2.77, compared to year-ago quarter EPS of $2.61. The current stock performance of Charles River shows a 52-week-high of $376.78 and a 52-week-low of $203.37. Moreover, at the end of the last trading period, the closing price was at $209.74.
With a Buy rating, Citigroup initiated coverage on Kimbell Royalty Partners LP (NYSE:KRP). The price target seems to have been set at $24.00 for Kimbell Royalty Partners. Kimbell Royalty Partners earned $0.55 in the second quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $20.08 and a 52-week-low of $13.75. Kimbell Royalty Partners closed at $18.16 at the end of the last trading period.
